Topical Ivermectin: Creams, Lotions and Use on the Skin

Topical ivermectin is ivermectin put on the skin as a cream, lotion or ointment, instead of being swallowed as a tablet. Two forms have been tested in controlled trials against the same product without ivermectin: a 1% cream for rosacea [1] and a 0.5% lotion for head lice [2]. Other studies and case reports describe a 1% ointment on the eyelids against Demodex mites [3], a 1% lotion for scabies [4], and a crushed ivermectin tablet placed on tissue infested with fly larvae [5].

This page goes deeper on use on the skin. The main Ivermectin page covers the drug as a whole, including the tablets, their approved uses and the safety record.

Table of Contents

  1. What Topical Ivermectin Is
  2. Rosacea and Demodex Mites
  3. Demodex Mites on the Eyelids
  4. Head Lice
  5. Scabies
  6. Myiasis and Infested Wounds
  7. How Much Reaches the Body
  8. Side Effects Reported
  9. Topical Use on the Gums
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Topical Ivermectin Is

Ivermectin is a derivative of the avermectins, a family of parasite-killing drugs known as macrocyclic lactones. Besides acting against a broad range of parasites, it has anti-inflammatory properties, and a 2015 review notes that both actions may contribute to its effect in rosacea [6]. Taken as a tablet, ivermectin is absorbed and carried through the body. Applied as a cream, lotion or ointment, it is put on the skin, where the mites and lice it is used against live.

A 2016 review of topical ivermectin in skin medicine sets out why these forms drew interest. Resistance to older insect-killing treatments, namely lindane, permethrin and possibly malathion, complicates the treatment of scabies and head lice worldwide, and ivermectin has been used safely and effectively against both infestations. The review adds that ivermectin may also be useful in inflammatory skin conditions such as papulopustular rosacea, in which Demodex mites may play a part [7].

The forms described in the research

Rosacea and Demodex Mites

Rosacea is a long-lasting skin condition of the face. A 2025 review describes four types: erythematotelangiectatic (persistent redness with small visible blood vessels), papulopustular (red bumps and pus-filled spots), phymatous (thickened skin) and ocular (affecting the eyes). The review lists ivermectin, with metronidazole, azelaic acid and minocycline, among the topical medicines used as first-line treatment for mild to moderate rosacea [9]. The site’s Rosacea page covers the condition and its other treatments.

Demodex folliculorum is a common mite of human skin, too small to be seen without a microscope, that lives in hair follicles. Rosacea is often accompanied by an increased density of this mite [10]. A 2018 systematic review (a structured search and summary of the published evidence) describes accumulating evidence that the mite is linked to papulopustular rosacea. It notes that established treatments such as metronidazole, azelaic acid and tetracyclines are thought to work through their anti-inflammatory effects, while the 1% ivermectin cream has both anti-inflammatory and mite-killing activity [11].

The two pivotal trials

In two identically designed randomized trials published in 2014, adults with moderate to severe papulopustular rosacea were assigned by chance to apply either the 1% cream or the vehicle (the same cream without ivermectin) once a day for 12 weeks. The trials were double-blind: neither the patients nor the doctors knew who had which [1].

Compared with metronidazole and other topical drugs

A 2015 review of the late-stage (phase III) trials, which lasted 12 or 16 weeks, found the once-daily ivermectin cream more effective than twice-daily metronidazole 0.75% cream on symptoms and on quality of life. According to extension studies, the cream went on providing benefit for up to 52 weeks of treatment [6].

The 2018 systematic review found three randomized trials, three extension studies and two meta-analyses (studies that pool the results of earlier trials). It noted that ivermectin had only been tested in moderate-to-severe papulopustular rosacea. At 12 weeks, ivermectin appeared more effective than metronidazole, with a number needed to treat of 10.5: about one extra person reached the outcome measured for every 10.5 people treated with ivermectin rather than metronidazole [11].

A 2025 meta-analysis pooled 21 randomized trials of six topical drugs for rosacea: minocycline, ivermectin, azelaic acid, metronidazole, brimonidine and oxymetazoline. It found ivermectin more effective than azelaic acid and metronidazole, and described all six as well tolerated and safe [12].

Relapse after treatment stops

The 2018 review found the cream widely adopted in clinical guidelines, and also found that rosacea commonly came back once treatment stopped. At week 36, ivermectin did slightly better than metronidazole at preventing relapse in raw numbers (number needed to treat 17.5), but relapse after stopping was common in both groups, with 62.7% and 68.4% of patients relapsing: about two-thirds of patients relapsed within 36 weeks. Working from evidence of limited generalizability, guidelines had produced different treatment plans and, in some areas, conflicting recommendations. The review called for more research on whether ivermectin’s mite-killing action helps prevent relapse, compared with other treatments not aimed at the cause [11].

Demodex mite counts before and after

A 2017 pilot study treated 20 patients who had moderate to severe rosacea and at least 15 Demodex mites per square centimetre of skin, using the 1% cream once a day for at least 12 weeks. Mites were counted in skin surface samples (skin surface biopsies). The average mite density was significantly lower at week 6 and at week 12 (P < 0.001). All 20 patients improved, and 16 of the 20 reached treatment success, a doctor’s rating of clear or almost clear skin [13].

A 2025 study examined patients before and after 30 days of the 1% cream. At day 30, mite density had fallen markedly in 87.5% of the patients [10].

A small 2026 study used dermoscopy (examining the skin through a lighted magnifier) to look for signs that predict who responds. Of 23 patients with moderate-to-severe papulopustular rosacea, 10 used ivermectin cream and 13 used metronidazole 1% gel once a day for 8 weeks; the doctors chose the treatment, so the groups were not randomized. An optimal response (more than 75% fewer lesions) occurred in 5 of 10 (50%) with ivermectin and 4 of 13 (31%) with metronidazole. All 5 ivermectin patients with an optimal response, and none of the other 5, had protruding follicular plugs at the start: small plugs in the hair openings that the authors describe as indicators of Demodex tails (p=0.004). In the metronidazole group the plugs did not predict a good response. The authors called for larger controlled trials to check the finding [14].

A 2025 meta-analysis pooled five studies (180 participants) of 1% topical ivermectin in Demodex-related skin conditions. All five reported significant falls in mite count or density after daily use. On average, density fell by 70.01 mites per square centimetre, and the share of people testing Demodex-positive (5 or more mites per square centimetre) fell by 80%. A 16-week course was associated with a notable reduction, with effects lasting up to 12 weeks after treatment ended. The authors noted that mites may repopulate after treatment, and that the small number of trials and the differences between studies call for cautious reading [15].

A 2023 meta-analysis compared anti-Demodex treatments across 21 studies, including ivermectin, tea tree oil, permethrin, crotamiton, metronidazole and light therapies. It measured each treatment’s effect size, a standard measure of how large the fall in mites was. Topical ivermectin had the largest effect size at 1 to 2 months (4.40) and at 2 to 3 months (8.37). In the first month the largest was for ivermectin with metronidazole taken by mouth (1.95), and after more than 3 months it was for intense pulsed light, a light treatment (2.25). Topical ivermectin, tea tree oil, permethrin, intense pulsed light and baby shampoo all achieved a nearly 100% decrease in mites. The authors named ivermectin (on the skin and by mouth), ivermectin combined with metronidazole on the skin, and tea tree oil on the skin as promising anti-Demodex treatments [16].

Inflammation signals in the skin

The 2017 pilot study also measured the activity of genes for five immune and inflammation signals in the skin: interleukin 8 (IL-8), the skin’s defence proteins LL-37 and human beta-defensin 3 (HBD3), the immune sensor toll-like receptor 4 (TLR4), and tumour necrosis factor alpha (TNF-α). All five were lower at both follow-up times. The drop was statistically significant for LL-37, HBD3 and TNF-α at both times, and for TLR4 at week 12. Lower LL-37 and IL-8 were confirmed at the protein level. The authors concluded that the cream works in two ways, against inflammation and against the parasites, killing Demodex mites in living skin [13].

The 2025 study of 30 days of treatment also looked at skin bacteria. Rosacea skin carried less Cutibacterium acnes and more Staphylococcus epidermidis than the skin of healthy volunteers, and the cream did not correct this imbalance; instead, the patients’ own gene activity in the skin moved significantly back towards normal. The authors concluded that improvement went with fewer mites and less disturbed gene activity, not with a return to normal skin bacteria [10]. A companion page covers ivermectin’s anti-inflammatory research.

Combined with doxycycline or lasers

A 2020 randomized trial enrolled 273 adults with severe rosacea (the top score, 4, on the doctor’s 0 to 4 severity scale). For 12 weeks all used the ivermectin cream; one group also took doxycycline 40 mg modified-release capsules, a low-dose form of the antibiotic, and the other a placebo (dummy) capsule. Inflammatory lesions fell by 80.3% with the combination and by 73.6% with the cream alone (P = .032). At week 12, 11.9% against 5.1% were rated clear (P = .043), and 17.8% against 7.2% had every lesion gone (P = .006). Both groups improved in redness, stinging or burning, flushing, quality of life and eye signs, and both treatments were well tolerated. The study was too short to judge whether rosacea came back [17].

A 2026 randomized split-face trial gave 24 people with rosacea four sessions of a potassium-titanyl-phosphate (KTP) laser at 532 nanometres, a vascular laser (one aimed at blood vessels) used for facial redness and visible vessels. One side of each face was also treated daily with the 1% cream, so each person served as their own comparison. At week 16, redness measured by the Normalized Erythema Index fell more on the ivermectin side: by 16.6% against 5.3% (p = 0.04). Other redness and severity scores showed no significant difference, but papules (red bumps) fell significantly more with ivermectin across the visits (p = 0.02). Both sides were well tolerated, with no serious side effects [18].

A 2022 trial randomly divided 30 patients between pulsed dye laser alone (a 585-nanometre laser used for the blood-vessel side of rosacea) and the same laser plus 1% ivermectin cream; each had four laser sessions 4 weeks apart. Three months after the last session, the combination group showed better clinical improvement, but the difference was not statistically significant. Neither group had serious side effects [19].

Rosacea of the scalp

Rosacea can also affect the scalp, where it is often misdiagnosed or overlooked, and no drug had been approved for that area. A 2024 report described 5 adults with inflammatory rosacea that also involved the scalp, confirmed by dermoscopy and tissue examination, who were treated effectively with the 1% cream once a day for 12 weeks. The authors called their experience limited [20].

Demodex Mites on the Eyelids

Blepharitis is inflammation of the eyelid edges. A 2025 study describes Demodex blepharitis as a common inflammatory eye condition, often overlooked, caused by an overgrowth of Demodex mites on the eyelids, in the eyelash follicles and in the oil glands of the lids [21]. The site’s Blepharitis page covers the condition in full.

An ivermectin ointment on the eyelids

A 2024 retrospective study (one that looks back at existing medical records) reviewed the records of an eye clinic in Buenos Aires, Argentina, from January 2017 to December 2022. It included 2,157 patients (4,314 eyes) with Demodex blepharitis who were treated with 1% ivermectin ointment once a day for 2 months and followed for at least 6 months; the average follow-up was 26.1 months. Before and after treatment [3]:

No one stopped treatment because they could not tolerate it; 14 people (0.6%) reported occasional discomfort. The authors concluded that the ointment, once a day for 2 months, reduced collarettes and improved symptoms [3].

Ivermectin by mouth for stubborn cases

The 2025 study quoted above treated 35 patients with long-standing blepharitis and cylindrical dandruff (sleeve-like crusts around the lashes) that had not responded to standard Demodex treatment. After the standard treatment, they took ivermectin by mouth: two doses of 0.2 mg per kilogram of body weight, 30 days apart. Their average Ocular Surface Disease Index score was 77.47 before the standard treatment and 6.69 after the ivermectin. The scores were taken at those two points, so the change spans both treatments. The authors described oral ivermectin as an effective option in cases unresponsive to standard treatment [21].

A laboratory comparison against the mites

In a 2025 laboratory study, adult Demodex mites taken from the eyelashes of people with blepharitis were placed one at a time under a microscope in a drop of a test substance. Each was timed until it stopped all movement for 60 seconds despite being prodded. Ten mites were tested with each substance. The median survival times were:

Lemongrass oil killed all of its mites fastest. The authors wrote that studies in living patients are needed to confirm the findings and to explore safety [22].

Head Lice

Head lice are small insects that live on the scalp and feed on blood. Infestation is common worldwide, especially in children 3 to 11 years old. The usual treatments are insecticide lotions, and resistance of lice to these insecticides, particularly the pyrethroids, causes treatment to fail [23].

The 0.5% lotion

A 2013 review of the 0.5% ivermectin lotion set out its place among treatments. In the United States, the recommended first-line treatments were permethrin 1% or pyrethrins, with malathion 0.5% lotion second-line. In 2 studies, significantly more of the 289 participants with head lice who used the ivermectin lotion were lice-free at day 15 than those using the vehicle lotion: 73.8% against 17.6% (P < .001). That rate was lower than for other third-line treatments such as spinosad 0.9% or benzyl alcohol 5%. The lotion was well tolerated: itching, the most common side effect, occurred in 0.9% [2].

The review explains how the lotion acts. Ivermectin raises chloride inside the lice’s muscle cells, which paralyses them. One application is enough, because when treated eggs hatch, the young lice cannot feed: the muscles of their throat are paralysed. The review found no documented resistance to it. It placed the lotion as a third-line treatment for head lice in the United States, because clinical experience was limited, it required a prescription and it was expensive [2].

In 2020, the Journal of the American Medical Association published an item titled “Ivermectin Lotion for Head Lice No Longer Needs a Prescription” [24]. Blood levels in young children after the lotion are described under How Much Reaches the Body, below.

Ivermectin by mouth, for comparison

In a 2010 randomized trial of 812 patients whose lice had survived an insecticide used 2 to 6 weeks earlier, ivermectin by mouth (400 micrograms per kilogram of body weight, on days 1 and 8) left 95.2% lice-free on day 15, against 85.0% with 0.5% malathion lotion, with no significant difference in side effects [23]. Tea tree oil, also studied against lice, is covered on the site’s page on tea tree oil for head lice and scabies.

Scabies

Scabies is a highly contagious skin disease caused by a mite, Sarcoptes scabiei [4]. A 2021 review describes the signs that point to it: thread-like burrows in the skin, new and intense itching, and inflamed skin, with the diagnosis confirmed by finding the mites under a microscope or a dermatoscope [25]. The site’s Scabies page covers the condition and its treatments.

Where ivermectin fits in scabies treatment

The ivermectin named in the 2021 review is the form taken by mouth. The review gives permethrin applied to the skin as the first-line treatment; ivermectin by mouth, crotamiton and benzyl benzoate as other options; and permethrin combined with ivermectin for otherwise intractable cases and, generally, for crusted scabies, a severe form with thick crusts. It reports a rising number of well-documented cases of poor response to permethrin, though no direct proof yet that the mites have become resistant to it [25]. A 2024 letter in a dermatology journal carried the title “Topical Ivermectin for Permethrin-Resistant Scabies: A Useful Application” [26].

Ivermectin lotion compared with permethrin lotion

A 2023 study at a military hospital in Rawalpindi, Pakistan, enrolled 354 patients with uncomplicated scabies and divided them randomly into two groups. One group and their family contacts used 1% ivermectin lotion; the other used 5% permethrin lotion. Results were reported for 159 patients in each group [4]:

Neither difference was statistically significant, and the authors described the two lotions’ results as almost identical. Side effects were minimal [4]. Trials of ivermectin tablets for scabies are covered on the main Ivermectin page.

Myiasis and Infested Wounds

Myiasis is infestation of living or dead tissue by fly larvae (maggots). In the mouth it is uncommon; a 2026 review links oral myiasis with poor oral hygiene, gum disease, neurological or psychiatric disability, cancer and social vulnerability [27]. Ivermectin placed directly on infested tissue appears in case reports. A 1999 case report in the International Journal of Dermatology was titled “Myiasis: a successful treatment with topical ivermectin” [28].

A crushed tablet inside the mouth

A 2023 case report described an 82-year-old man with a fixed bridge supported by dental implants. Fly larvae, in considerable numbers, had spread through the space between his cheeks and gums and along the gum ridge of his upper jaw on both sides, and over a large part of his palate (the roof of the mouth). Treatment went in steps [5]:

  1. A single 6 mg dose of ivermectin by mouth, and a swab soaked in ether placed on the area.
  2. Surgical removal of the larvae and cleaning of the wound (debridement).
  3. A crushed 6 mg ivermectin tablet applied directly to the tissue for 2 days.
  4. Removal of the remaining larvae, and antimicrobial medicine through a drip.

The authors concluded that ivermectin by mouth and on the tissue, combined with antibiotics and debridement, “proved to be effective” [5]. The site’s Oral Myiasis page covers fly larvae in the mouth in more detail.

A wound around a kidney drainage tube

A 2021 case report described a 55-year-old farmer who went home with a nephrostomy tube, a drainage tube running through the skin into the kidney. Two weeks later he came back with severe pain and itching around the tube; the wound hygiene was poor, and there were maggots around the tube. They were treated by putting turpentine oil into the wound and giving ivermectin both by mouth and on the skin, followed by removing the maggots by hand [29].

Treatment in recent published cases

The 2026 review analysed 14 case reports and case series, published from 2020 onward, of myiasis confined to the mouth. It found treatment “consistently multimodal”, combining removal of the larvae by hand with antibiotics, ivermectin, surgical cleaning and agents applied to the tissue. The patients were mainly medically and socially vulnerable, and the review describes oral myiasis as potentially life-threatening in critically ill people [27].

How Much Reaches the Body

A 2013 study measured blood levels in 30 children aged 6 months to 3 years who had head lice. Each had a single 10-minute application of the 0.5% lotion on day 1. Blood was drawn before the application; at 0.5, 1 and 6 hours after rinsing; and on days 2 and 8. Samples from 20 of the children were tested for ivermectin, with a test able to detect 0.05 nanograms per millilitre (a nanogram is a billionth of a gram). Every ivermectin level detected was below 1 nanogram per millilitre. Liver tests and blood counts were done in all the children, and no safety signals emerged. The authors described absorption as minimal, and wrote that the results support the safety of the lotion in children as young as 6 months [8].

The 2013 review of the lotion likewise reports minimal absorption into the body after use on the skin [2], and the 2025 Demodex meta-analysis observed no side effects elsewhere in the body with 1% topical ivermectin [15].

A 2016 review of scabies and lice treatments used on the skin in pregnancy notes that medicines applied to the skin have little absorption into the body, and so are considered less likely than medicines taken by mouth or injected to harm an embryo or fetus. It adds that the available safety data are limited [30].

Side Effects Reported

Topical Use on the Gums

The site’s page on ivermectin for gum disease describes accounts shared in Telegram chat groups, in which members put ivermectin paste, the oral paste sold for horses, directly on their gums, repeat it several times, and report that their gums healed. These are personal accounts from the chats, not published studies. The research summarised on this page includes no trial of ivermectin applied to the gums; the closest published report is the 2023 case above, in which a crushed ivermectin tablet was placed on infested tissue in the mouth together with removal of the larvae and antibiotics [5]. Ivermectin products made for animals are the subject of the Veterinary Ivermectin page.

Key Research Papers

  1. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316-23. PubMed PMID: 24595578
  2. Deeks LS, Naunton M, Currie MJ, Bowden FJ. Topical ivermectin 0.5% lotion for treatment of head lice. Ann Pharmacother. 2013;47(9):1161-7. PubMed PMID: 24259731
  3. Valvecchia F, Greco L, Perrone F, Logioco C, Caride GG, Perrone L, et al. Topical ivermectin ointment treatment of Demodex blepharitis: a 6-year retrospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1281-1288. PubMed PMID: 37910180
  4. Saeed A, Tariq S, Iqbal M, Ismaeel H, Mashhood A, Raza MH, et al. Study Comparing Topical Ivermectin Versus Topical Permethrin in the Treatment of Scabies. Cureus. 2023;15(11):e48746. PubMed PMID: 38094520
  5. Sangalette BS, Bortoloto JGP, Pavoni RF, Cappellari VI, Capelari MM, Shinohara AL, et al. Treatment of oral myiasis in a patient with implant-supported fixed prosthesis. Rev Inst Med Trop Sao Paulo. 2023;65:e27. PubMed PMID: 37075334
  6. Deeks ED. Ivermectin: A Review in Rosacea. Am J Clin Dermatol. 2015;16(5):447-52. PubMed PMID: 26254001
  7. Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J. 2016;22(9). PubMed PMID: 28329606
  8. Hazan L, Berg JE, Bowman JP, Murray JV, Ryan WG. Pharmacokinetics and safety of 0.5% ivermectin lotion for head louse infestations. Pediatr Dermatol. 2013;30(3):323-8. PubMed PMID: 23131185
  9. Volk K, Ulfers A, Yi RC, Feldman S, Taylor SL. Treatment management for rosacea: current pharmacological and non-pharmacological options. Expert Rev Clin Pharmacol. 2025;18(8):589-605. PubMed PMID: 40836652
  10. Olah P, Reuvers N, Radai Z, Varadi A, van Lierop A, Wachtmeister T, et al. Microbe-Host Interaction in Rosacea and Its Modulation through Topical Ivermectin. J Invest Dermatol. 2025;145(10):2576-2587.e8. PubMed PMID: 40220854
  11. Ebbelaar CCF, Venema AW, Van Dijk MR. Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. Dermatol Ther (Heidelb). 2018;8(3):379-387. PubMed PMID: 29943217
  12. Gao X, Xiang W. Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis. Actas Dermosifiliogr. 2025;116(8):863-875. PubMed PMID: 40246142
  13. Schaller M, Gonser L, Belge K, Braunsdorf C, Nordin R, Scheu A, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31(11):1907-1911. PubMed PMID: 28653460
  14. Plozner N, Lai M, Figini M, Mehta N, Szykut-Badaczewska A, Kyrgidis A, et al. Dermoscopic Response Predictors in Papulopustular Rosacea Treated with Topical Ivermectin and Metronidazole: A Prospective Observational Comparative Study. Clin Cosmet Investig Dermatol. 2026;19:589715. PubMed PMID: 41716253
  15. Paichitrojjana A, Khuancharee K, Paichitrojjana A. Efficacy of topical Ivermectin in controlling human Demodex infestation: Evidence from systematic review and meta-analysis. Parasite Epidemiol Control. 2025;31:e00461. PubMed PMID: 41103378
  16. Li J, Wei E, Reisinger A, French LE, Clanner-Engelshofen BM, Reinholz M. Comparison of Different Anti-Demodex Strategies: A Systematic Review and Meta-Analysis. Dermatology. 2023;239(1):12-31. PubMed PMID: 36310014
  17. Schaller M, Kemény L, Havlickova B, Jackson JM, Ambroziak M, Lynde C, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336-343. PubMed PMID: 31150711
  18. Heidemeyer K, Cazzaniga S, Junge A, Lehmann M, Seyed Jafari SM, Yawalkar N, et al. Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial. J Dermatolog Treat. 2026;37(1):2635882. PubMed PMID: 41778357
  19. Osman M, Shokeir HA, Hassan AM, Atef Khalifa M. Pulsed dye laser alone versus its combination with topical ivermectin 1% in treatment of Rosacea: a randomized comparative study. J Dermatolog Treat. 2022;33(1):184-190. PubMed PMID: 32141785
  20. Dall'Oglio F, Nasca MR, Guglielmi G, Micali G. Scalp Rosacea Treated with Topical Ivermectin. Skin Appendage Disord. 2024;10(5):429-432. PubMed PMID: 39386311
  21. Alver O, Doğanay D, Doğanay S. Effectiveness of Oral Ivermectin Treatment in Cases Unresponsive to Classical Demodex Blepharitis Treatment. Turkiye Parazitol Derg. 2025;49(4):168-172. PubMed PMID: 41324283
  22. Demirci G, Erdur SK. Comparative in vitro efficacy of ivermectin, lotilaner, lime sulfur, tea tree oil, and lemongrass oil against Demodex folliculorum. Cont Lens Anterior Eye. 2025;48(6):102481. PubMed PMID: 40721364
  23. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010;362(10):896-905. PubMed PMID: 20220184
  24. Voelker R. Ivermectin Lotion for Head Lice No Longer Needs a Prescription. JAMA. 2020;324(21):2147. PubMed PMID: 33258878
  25. Sunderkötter C, Wohlrab J, Hamm H. Scabies: Epidemiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2021;118(41):695-704. PubMed PMID: 34615594
  26. Gnesotto L, Cutrone M, Mazzatenta C, Bassi A, Piccolo V, Sechi A. Topical Ivermectin for Permethrin-Resistant Scabies: A Useful Application. Dermatol Pract Concept. 2024;14(1). PubMed PMID: 38364400
  27. Monsalves N, Estrada F, Venegas J. Oral Myiasis: A Structured Review of Risk Factors, Clinical Presentation, and Treatment. Cureus. 2026;18(9):e116137. PubMed PMID: 42733919
  28. Victoria J, Trujillo R, Barreto M. Myiasis: a successful treatment with topical ivermectin. Int J Dermatol. 1999;38(2):142-4. PubMed PMID: 10192168
  29. Mulawkar PM, Agrawal SG, Mulawkar UP, Panpaliya GS. Myiasis (maggots) around nephrostomy tube. Urol Ann. 2021;13(4):438-441. PubMed PMID: 34759660
  30. Patel VM, Lambert WC, Schwartz RA. Safety of Topical Medications for Scabies and Lice in Pregnancy. Indian J Dermatol. 2016;61(6):583-587. PubMed PMID: 27904173

PubMed Topic Searches

  1. PubMed: Topical ivermectin and rosacea
  2. PubMed: Ivermectin cream and Demodex density
  3. PubMed: Ivermectin and Demodex blepharitis
  4. PubMed: Ivermectin lotion and head lice
  5. PubMed: Topical ivermectin and scabies
  6. PubMed: Topical ivermectin and myiasis

Back to Table of Contents

Connections

Back to Table of Contents